PUBLIC COMPANY
saveOTSUKA
USupdated 4mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Deep dive: Psychedelics back on FDA’s doorstepBioSpace takes stock of the psychedelic therapeutics space, which is once again on the cusp of its first FDA approval.biospace · 2d ago
- 5 biotechs braving the commercial waters with product launchesA growing number of biotechs are entering the market with newly launched medicines, a pattern indicative of “improving capital markets,” according to Jefferies’ Andrew Tsai.biospace · 3d ago
- Psychedelic therapies ride wave of public favor into FDA hearingHeading into an FDA hearing on Monday regarding the future of psychedelic treatments, public comments show wide support for further exploring the therapeutic potential of these compounds—to match r…biospace · 5d ago
- Psilocybin proves promising in neuropathic pain mouse studyAmid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.fiercebiotech · 15d ago
- Lilly partners with Amplitude on vaccines; Otsuka scraps psychedelic trialPlus news about AC Immune, Lilly's Adverum and SiranBio. 🤝 Eli Lilly signs vaccine deal with Amplitude: The companies will work to develop vaccines using “trans-amplifying RNA,” or taRNA, for infe…endpoints · 29d ago
- Vera’s newly approved IgA nephropathy drug supports kidney function, like Otsuka’s VoyxactOtsuka Pharmaceuticals’ Voyxact is not the only IgA nephropathy drug that can slow the decline of kidney function. Vera Therapeutics’ Trutakna, which the FDA granted accelerated approval last month…biospace · 1mo ago
- Boulevard starts up with $65M to pursue targeted autoimmune drugsCo-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several immune diseases.biopharma_dive · 1mo ago
- Otsuka succeeds with kidney drug; BioNTech downgrades revenue projection✅ Otsuka’s confirmatory kidney disease data: The drugmaker said Voyxact met a key secondary endpoint in the Phase 3 VISIONARY study in patients with IgA nephropathy (IgAN). The treatment increased…endpoints · 1mo ago
- Vertex unfazed by competitive IgAN space as FDA verdict loomsPositive two-year follow-up data for Otsuka Pharmaceuticals’ IgA nephropathy drug Voyxact could support the FDA’s ongoing review of Vertex Pharmaceuticals’ povetacicept, CEO Reshma Kewalramani said…biospace · 1mo ago
- Eli Lilly tops new biopharma ranking on launch success, development speedFlush with GLP-1 cash and pipeline success, Eli Lilly rose from 16th to first over five years in Norstella’s inaugural Pipeline-to-Patient Productivity Index, which evaluated 25 large, global bioph…fiercebiotech · 1mo ago
comments(0)
5-min edit window · permanent after that